Optimal dose for renoprotection by the angiotensin II receptor blocker candesartan in patients with type 2 diabetes and nephropathy.

被引：0
|
作者：
Rossing, K
Christensen, PK
Jacobsen, PK
Hansen, BV
Parving, HH
机构：
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Univ Aarhus, Fac Hlth Sci, DK-8000 Aarhus C, Denmark
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：653A / 653A
页数：1
相关论文
共 50 条
  • [1] Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
    Hou, Fan Fan
    Zhou, Qiu Gen
    NEPHROLOGY, 2010, 15 : 57 - 60
  • [2] Renoprotective effects of adding an angiotensin II receptor blocker to maximal recommended doses of ACE-inhibitor in patients with Type 2 diabetes and nephropathy.
    Rossing, K
    Jacobsen, P
    Pietraszek, L
    Parving, HH
    DIABETOLOGIA, 2003, 46 : A338 - A339
  • [3] Combined treatment of prednisolone and angiotensin II receptor blocker in IgA nephropathy.
    Ihm, CG
    Lee, SH
    Lee, SH
    Kim, YH
    Lee, T
    Kim, MJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 752A - 752A
  • [4] Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice
    Liao, J
    Kobayashi, M
    Kanamuru, Y
    Nakamura, S
    Makita, Y
    Funabiki, K
    Horikoshi, S
    Tomino, Y
    JOURNAL OF NEPHROLOGY, 2003, 16 (06) : 841 - 849
  • [5] Angiotensin II receptor blocker: Candesartan cilexetil
    Inada, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 35P - 35P
  • [6] Candesartan cilexetil: An angiotensin II receptor blocker
    Stoukides, CA
    McVoy, HJ
    Kaul, AF
    ANNALS OF PHARMACOTHERAPY, 1999, 33 (12) : 1287 - 1298
  • [7] Effects of high dose angiotensin II receptor blocker - comparison of Valsartan and Candesartan
    Ohishi, Mitsuru
    Ito, Norihisa
    Takagi, Takashi
    Terai, Minako
    Tatara, Yuji
    Shiota, Atsushi
    Hayashi, Norihiro
    Katsuya, Tomohiro
    Rakugi, Hiromi
    Ogihara, Toshio
    JOURNAL OF HYPERTENSION, 2006, 24 : 364 - 364
  • [8] Diabetes-associated cognitive impairment is improved by angiotensin II type 1 receptor blocker, candesartan
    Tsukuda, Kana
    Mogi, Masaki
    Li, Jian-Mei
    Iwanami, Jun
    Min, Li-Juan
    Sakata, Akiko
    Iwai, Masaru
    Horiuchi, Masatsugu
    STROKE, 2007, 38 (02) : 523 - 523
  • [9] Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy - A double-blind randomized cross-over study
    Rossing, K
    Christensen, PK
    Hansen, BV
    Carstensen, B
    Parving, HH
    DIABETES CARE, 2003, 26 (01) : 150 - 155
  • [10] Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis, B.
    Page, S. R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (12) : 1995 - 2007
12345